For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition. Below is the list of 10 drugs covered under Medicare Part D selected for negotiation for initial price applicability year 2026, based on total gross covered prescription drug costs under Medicare Part D and other criteria as required by the IRA (Inflation Reduction Act). These drugs are branded and include the following:

1. Eliquis
2. Jardiance
3. Xerelto
4. Januvia
5. Farxiga
6. Entresto
7. Embrel
8. Imbruvica
9. Stelara
10. Fiasp; Fiasp FlexTouch; FiaspPenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill

Details and time frames for this negotiation are laid out in this Fact Sheet.